Jinxin Fertility Group (OTCMKTS:JXFGF) is a Cayman Islands–incorporated company that provides a full spectrum of assisted reproductive and fertility services through its network of clinics and laboratory facilities in mainland China. The company offers in vitro fertilization (IVF), intrauterine insemination (IUI), egg and sperm cryopreservation, pre-implantation genetic testing and counseling, and related reproductive health services designed to support couples and individuals seeking to build families.
Since its founding in 2014, Jinxin Fertility Group has expanded its presence into multiple major cities, partnering with local hospitals and healthcare institutions to deliver standardized clinical protocols and advanced laboratory capabilities. Its integrated model brings together patient consultation, diagnostic testing, treatment planning and follow-up care under a centralized quality management system, enabling consistent outcomes and streamlined patient experiences.
In addition to core fertility treatments, the company provides genetic screening and risk assessment services, hormone and fertility monitoring, and personalized care plans tailored to complex clinical cases. Jinxin Fertility Group’s proprietary laboratory platform employs advanced embryology techniques and goes beyond traditional IVF by incorporating technologies such as time-lapse embryo monitoring and comprehensive chromosomal screening.
Serving clients across China’s tier-1 and tier-2 cities, Jinxin Fertility Group continues to invest in research collaborations, digital health initiatives and staff training to maintain clinical excellence. Its management team combines expertise in reproductive medicine, laboratory science and healthcare operations, positioning the company to address evolving patient needs in China’s growing fertility services market.
AI Generated. May Contain Errors.